-
Cannatrek leads advancement in medical cannabis research with its signing of a MoU with Mie University in Tsu, Japan
-
The MoU focuses on a collaborative effort from both parties to further agronomic and medical research for medical cannabis
Cannatrek, Australia’s leading vertically integrated plant-based medicine company, has signed a Memorandum of Understanding (MoU) with Mie University in Tsu, Japan, to forge an open collaboration focused on accelerating medical research into the use of cannabis.
The strategic partnership marks the first-ever MoU for medicinal cannabis research between any Australian and Japanese organisation or government.
The MoU swiftly follows the Japanese Government’s recent change in stance towards the use of cannabis with the Lower House passing the bill to legalise the use of medical products made from cannabis in mid-November.
“We are honoured to be the first Australian business to have a MoU for medicinal cannabis research with a Japanese organisation” says Cannatrek CEO Tommy Huppert.
“Cannatrek has the manufacturing capability to supply the highest quality of medicinal cannabis products for domestic and international markets via our Shepparton facility. The facility recently received Good Manufacturing Practice (GMP) accreditation which further enhances export opportunities”.
Under the MoU, the framework for cooperation encompasses several key areas including agronomic research, training resources for clinicians, pharmaceutical supply chain, e-healthcare, navigating regulation and compliance and connecting experts in the field.
